About 40% of the population exposed to the risk of P. vivax infection in southeast Asia, where relevant data are available, is not eligible for the standard anti-relapse treatment with primaquine due to G6PD deficiency and may face treatment failure due to poor drug metabolism [103]. The gene discussed is G6PD; the disease is hyperinsulinemic hypoglycemia, familial, 4.